You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
MDPI is pleased to announce the launch of Biomedicines (ISSN 2227-9059), a new journal aimed at bridging the gap between biological research and clinical practice, led by the Editor-in-Chief Prof. Dr. Kenneth Cornetta. Biomedicines provides a forum for all aspects related to biomedicines—medicines that are made from, or contain, biological active substances. Biomedicines welcomes theoretical and research papers in the field of biologic agents. These include vaccines, monoclonal antibodies, immunotherapy, cell therapeutics, and gene therapy.
The Founding Editor-in-Chief Prof. Dr. Kenneth Cornetta from The Department of Medical and Molecular Genetics, Indiana University School of Medicine mainly works on gene therapy work. His research focus is on using viral based gene transfer as a means of introducing genetic sequences that will correct mutations and ameliorate disease. To date Dr. Cornetta’s lab has certified over 30 products for Phase I/II trials and has published extensively on release testing to meet FDA requirements.We hope that Biomedicines will become an invaluable resource to those working in basic scientific studies, product development, product manufacture, clinical trials and the wider scientific community.